Dear Judy
Thermography, which is also called thermal imaging or infrared imaging, was approved by the U.S. Food and Drug Administration in 1982 as a supplement to mammography in helping to detect breast cancer. This exam has not gained acceptance in the medical community as a necessary or useful in breast cancer detection since numerous studies have not shown the value as a screening, diagnostic or effective tool in addition to screening mammography to detect breast cancer.
Thermography is appealing to some women because it is a pain-free exam, but research over the last 20 years has shown that thermography is not reliable for detecting breast cancer. In 1977, a committee of the National Cancer Institute recommended that thermography be discontinued as a routine screening modality in the Breast Cancer Detection Demonstration Project where it was being evaluated along with mammography and ultrasonography. This does not mean that an improved thermography technology may not be useful in the future to aid in the diagnosis of breast cancer and currently there is research using computerized thermal imaging (CTI) which uses the principle of traditional thermography with the addition of digital image reconstruction. This technology has not been approved by the FDA and is currently being studied.
The theory behind thermography is that any local abnormality in the breast may cause an alteration in the temperature in that region. This may give false positives as well as false negatives and prior studies of thermography have shown a false positive rate of 25%. It is hoped that the addition of computerized reading using digital images of the thermogram may lead to a reduction in the false positive rate in the future. Also, microcalcifications, which are tiny calcium deposits that may indicate the presence of cancer are not seen on thermography. Up to 50% of breast cancers detected by mammography appear as these clusters of microcalcifications.
Philomena F. McAndrew, M.D.